Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer

Advanced Solid Cancer Clinical Trial

Official title:

A Phase I, Open-label Study to Assess the Safety and Tolerability of Ascending Doses of SH-1028 Tablets in Patients With Advanced Solid Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03618043
• Other study ID #: SHC013-I-02
• Status: Recruiting
• Phase: Phase 1
• Start date: September 13, 2018
• Est. completion date: December 2019

Study information

• Verified date: August 2018
• Source: Nanjing Sanhome Pharmaceutical, Co., Ltd.
• Contact: JIN LI, MD
• Phone: 021-38804518
• Email: lijin[@]csco.org.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1, open-label study of SH-1028 with dose escalation cohorts in locally advanced solid cancer patients who have progressed following prior therapy with an epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor (TKI) agent or standard treatment.

Description:

The study is designed to evaluate safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of once-daily and orally (PO) administered SH-1028 tablets. The overall study design is shown in the flow chart below.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 14
• Est. completion date: December 2019
• Est. primary completion date: December 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age from 18 to 75, both sexes.

2. Histologically or cytologically documented and Patients with advanced malignant solid tumors who have failed standard treatment, or have no standard treatment regimen, or are not eligible for standard treatment at this stage.

3. Confirmation that the tumor harbors an EGFR mutation known to be associated with EGFR TKI sensitivity :

1. For NSCLC patients, radiological documentation of disease progression while on a previous continuous treatment with an EGFR TKI, e.g., gefitinib or erlotinib. In addition, other lines of therapy may have been given; patients must have confirmation of T790M+ mutation status.

2. For other solid cancer patients, they have failed standard treatment, or have no standard treatment regimen and have confirmation that mutation of EGFR pathway is negative.

4. World Health Organization (WHO) performance status equal to 0-1.

5. A minimum life expectancy of 12 weeks.

6. At least 1 lesion that has not previously been irradiated.

7. Adequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:

1. Absolute neutrophil count > 1.5 x 109/L.

2. Platelet count > 100 x 109/L.

3. Hemoglobin > 90 g/L (< 9 g/dL).

4. Alanine aminotransferase < 2.5 times the upper limit of normal (ULN) if no demonstrable liver metastases or < 5 times the ULN in the presence of liver metastases.

5. Aspartate aminotransferase < 2.5 times the ULN if no demonstrable liver metastases or < 5 times the ULN in the presence of liver metastases.

6. Total bilirubin < 1.5 times the ULN if no liver metastases or < 3 times the ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases.

7. Creatinine < 1.5 times the ULN concurrent with creatinine clearance > 50 mL/min (measured or calculated by the Cockcroft - Gault equation); confirmation of creatinine clearance is only required when creatinine is < 1.5 times the ULN.

8. Females of child-bearing potential should be using adequate contraceptive measures throughout the study, should not be breast feeding during the study and until 6 months after completion of study, and must have a negative pregnancy test prior to start of dosing.

9. Male patients should be willing to use barrier contraception during the study and until 6 months after completion of study (i.e., condoms);

10. Do not anticipate other clinical trail in 1 months.

11. the patient must provide a written informed consent for genetic research.

Exclusion Criteria:

1. An EGFR TKI within 8 days or approximately 5 times the half-life of the specific drug, whichever is longer, of the first dose of study treatment.

2. Any radiation, cytotoxic chemotherapy, target medicines (except EGFR-TKI), endocrine therapy or immunotherapy used for a previous treatment regimen or clinical study within 28 days of the first dose of study treatment.

3. Ever used the third EGFR-TKI, such as AZD9291,CO-1686 or avitinib.

4. Major surgery within 4 weeks of the first dose of study treatment.

5. Radiotherapy with a limited field of radiation for palliation within 1 week of the first dose of study treatment, with the exception of patients receiving radiation to more than 30% of the bone marrow or with a wide field of radiation which must be completed within 4 weeks of the first dose of study treatment.

6. The patient is currently using (or cannot discontinue at least 1 week before the first dose of study treatment) a drug or herbal supplement known as a potent inhibitor or inducer of CYP3A4.

7. Use large doses of glucocorticoids or other immunosuppressive agents within 4 weeks.

8. Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE), Grade 1, at the time of starting study treatment with the exception of alopecia and Grade 2, prior platinum-therapy related neuropathy.

9. Spinal cord compression or brain metastases unless asymptomatic, stable, and not requiring steroids for at least 4 weeks prior to start of study treatment.

10. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension or active bleeding diatheses, which, in the Investigator's opinion, makes it undesirable for the patient to participate in the trial.

11. Active infection (e.g., hepatitis B, hepatitis C or human immunodeficiency virus [HIV]). (HBsAg is positive but HBV-DNA <1×103 bp / mL ).

12. Any of the following cardiac criteria:

1. Mean resting corrected QT interval (QTc) > 470 msec obtained from 3 electrocardiograms (ECGs), using the Screening clinic ECG machine and Fridericia's formula for QT interval correction.

2. Any clinically important abnormalities in rhythm, conduction, or morphology of the resting ECG (e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, PR interval >250msec).

3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval.

13. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.

14. Refractory nausea, vomiting, or chronic gastrointestinal diseases, inability to swallow the study medication, or previous significant bowel resection that would preclude adequate absorption of SH-1028.

15. History of hypersensitivity to any active or inactive ingredient of SH-1028 or to a drug with a similar chemical structure or class to SH-1028.

16. Women who are breast feeding.

17. Any disease or condition that, in the opinion of the Investigator, would compromise the safety of the patient or interfere with study assessments.

Related Conditions & MeSH terms

• Advanced Solid Cancer

Intervention

Drug:
• SH-1028
Starting dose 60mg,oral administered once daily.If tolerated subsequent cohorts will test increasing doses (120mg,180mg,240mg,320mg) of SH-1028.

Locations

Country	Name	City	State
China	Shanghai east hospital	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose (MTD)		Within the first 28 days of treatment
Primary	Incidence of Dose Limiting Toxicity (DLT)		Within the first 28 days of treatment
Secondary	Area under the plasma concentration versus time curve (AUC) of SH-1028		4 weeks
Secondary	Elimination half-life(T1/2) of SH-1028		4 weeks
Secondary	Maximum (or peak) concentration of SH-1028		4 weeks
Secondary	Overall Response Rate		12 months
Secondary	Disease control rates(DCR)		12 months